Essential thrombocythemia versus early primary myelofibrosis: A multicenter study to validate the WHO classification

Blood

Volumn 117, Issue 21, 2011, Pages 5710-5718

  Thiele, Jürgen ^a   Kvasnicka, Hans Michael ^a   Müllauer, Leonhard ^b   Buxhofer Ausch, Veronika ^b   Gisslinger, Bettina ^b   Gisslinger, Heinz ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BONE MARROW; BONE MARROW BIOPSY; CLINICAL EVALUATION; COHORT ANALYSIS; DISEASE CLASSIFICATION; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELOID METAPLASIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; THROMBOCYTHEMIA; WORLD HEALTH ORGANIZATION;

EID: 79957611312     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-293761     Document Type: Article

References (43)

1. Swerdlow S, Campo E, Harris N, et al. WHO Classification of Tumours of Haematopoietic and Lympoid Tissues. Lyon, France: IARC Press; 2008.
2. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-1097. (Pubitemid 47281402)
3. Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008;112(2):231-239.
4. Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood. 2008;111(1):60-70.
5. Campbell PJ, Bareford D, Erber WN, et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol. 2009;27(18):2991-2999.
6. Florena AM, Tripodo C, Iannitto E, Porcasi R, Ingrao S, Franco V. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica. 2004;89(8):911-919.
7. Gianelli U, Vener C, Raviele PR, et al. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. Leuk Lymphoma. 2006;47(9):1774-1781. (Pubitemid 44649759)
8. Thiele J, Kvasnicka HM. Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features: a clinicopathological study on 272 patients. Histol Histopathol. 2003;18(1):93-102. (Pubitemid 36040452)
9. Thiele J, Kvasnicka HM. Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders. Semin Thromb Hemost. 2006;32(3):219-230.
10. Kreft A, Buesche G, Ghalibafian M, Buhr T, Fischer T, Kirkpatrick CJ. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies. Acta Haematol. 2005;113(2):137-143.
11. Buhr T, Buesche G, Choritz H, Langer F, Kreipe H. Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. Am J Clin Pathol. 2003;119(1):152-158. (Pubitemid 37047910)
12. Thiele J, Kvasnicka HM, Schmitt-Gräff A, Diehl V. Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients. Leuk Lymphoma. 2003;44(6):549-553.
13. Thiele J, Kvasnicka HM, Schmitt-Graeff A, Zankovich R, Diehl V. Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients. Am J Hematol. 2002;70(4):283-291. (Pubitemid 34810505)
14. Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol. 2003;82(3):148-152. (Pubitemid 36700994)
15. Kvasnicka HM, Thiele J. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. Semin Thromb Hemost. 2006;32(4):362-371.
16. Jaffe E, Harris N, Stein H, Vardiman J. WHO Classification of Tumours of Haematopoietic and Lympoid Tissues. Lyon, France: IARC Press; 2001.
17. Thiele J, Kvasnicka HM, Diehl V. Standardization of bone marrow features: does it work in hematopathology for histological discrimination of different disease patterns? Histol Histopathol. 2005;20(2):633-644.
18. Thiele J, Kvasnicka HM. Hematopathologic findings in chronic idiopathic myelofibrosis. Semin Oncol. 2005;32(4):380-394. (Pubitemid 41073751)
19. Thiele J, Kvasnicka HM. Myelofibrosis in chronic myeloproliferative disorders: dynamics and clinical impact. Histol Histopathol. 2006;21(12):1367-1378. (Pubitemid 44614518)
20. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
21. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-174. (Pubitemid 8054849)
22. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-ofcare diagnostic algorithms. Leukemia. 2008;22(1):14-22.
23. Shih LY, Lee CT. Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay. Blood. 1994;83(3):744-748.
24. Jantunen R, Juvonen E, Ikkala E, Oksanen K, Anttila P, Ruutu T. Development of erythrocytosis in the course of essential thrombocythemia. Ann Hematol. 1999;78(5):219-222. (Pubitemid 29259600)
25. Thiele J, Kvasnicka HM, Diehl V. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol. 2005;113(4):213-219. (Pubitemid 40911544)
26. Gianelli U, Iurlo A, Vener C, et al. The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia. Am J Clin Pathol. 2008;130(3):336-342.
27. Rüdiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 2002;13(1):140-149. (Pubitemid 34436738)
28. Lones MA, Auperin A, Raphael M, et al. Mature B-cell lymphoma/leukemia in children and adolescents: intergroup pathologist consensus with the revised European-American Lymphoma Classification. Ann Oncol. 2000;11(1):47-51. (Pubitemid 30084578)
29. Glaser SL, Dorfman RF, Clarke CA. Expert review of the diagnosis and histologic classification of Hodgkin disease in a population-based cancer registry: interobserver reliability and impact on incidence and survival rates. Cancer. 2001;92(2):218-224. (Pubitemid 32664425)
30. Vener C, Fracchiolla NS, Gianelli U, et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood. 2008;111(4):1862-1865. (Pubitemid 351451494)
31. Boiocchi L, Vener C, Savi F, et al. Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasms. J Clin Pathol. 2011;64(3):226-231.
32. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study of 1104 patients. J Clin Oncol. In press.
33. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353(1):33-45. (Pubitemid 41007805)
34. Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol. 2010;85(1):62-69.
35. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 1997;34(1):29-39. (Pubitemid 27063140)
36. Bauermeister DE. Quantitation of bone marrow reticulin: a normal range. Am J Clin Pathol. 1971;56(1):24-31.
37. Buhr T, Georgii A, Choritz H. Myelofibrosis in chronic myeloproliferative disorders: incidence among subtypes according to the Hannover Classification. Pathol Res Pract. 1993;189(2):121-132. (Pubitemid 23123616)
38. Georgii A, Buesche G, Kreft A. The histopathology of chronic myeloproliferative diseases. Baillieres Clin Haematol. 1998;11(4):721-749. (Pubitemid 29452760)
39. Thiele J, Kvasnicka HM, Vardiman JW, et al. Bone marrow fibrosis and diagnosis of essential thrombocythemia. J Clin Oncol. 2009;27(34):e220-e221.
40. Brousseau M, Parot-Schinkel E, Moles MP, Boyer F, Hunault M, Rousselet MC. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. Histopathology. 2010;56(6):758-767.
41. Chim CS, Kwong YL, Lie AK, et al. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med. 2005;165(22):2651-2658. (Pubitemid 41785064)
42. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, longterm complication rates, and prognostic factors. Mayo Clin Proc. 2006;81(2):159-166.
43. Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93(11):1645-1651.